The role of ADME pharmacogenomics in early clinical trials: perspective of the Industry Pharmacogenomics Working Group (I-PWG).

Genetic polymorphisms in metabolizing enzymes and drug transporters have been shown to significantly impact the exposure of drugs having a high dependence on a single mechanism for their absorption, distribution or clearance, such that genotyping can lead to actionable steps in disease treatment. Recently, global regulatory agencies have provided guidance for assessment of pharmacogenomics during early stages of drug development, both in the form of formal guidance and perspectives published in scientific journals. The Industry Pharmacogenomics Working Group (I-PWG), conducted a survey among member companies to assess the practices relating to absorption, distribution, metabolism, excretion pharmacogenomics) during early stages of clinical development, to assess the impact of the recent Regulatory Guidance issued by the US FDA and EMA on Industry practices.

[1]  I. Overview.  Optimizing FDA ’ s Regulatory Oversight of Next Generation Sequencing Diagnostic Tests — Preliminary Discussion , 2014 .

[2]  M. Niemi.  Transporter Pharmacogenetics and Statin Toxicity , 2010, Clinical pharmacology and therapeutics.

[3]  N. Penner,et al.  Radiolabeled absorption, distribution, metabolism, and excretion studies in drug development: why, when, and how? , 2012, Chemical research in toxicology.

[4]  A. Snapir,et al.  Current Practices for DNA Sample Collection and Storage in the Pharmaceutical Industry, and Potential Areas for Harmonization: Perspective of the I‐PWG , 2011, Clinical pharmacology and therapeutics.

[5]  S. Dubovsky.  The usefulness of genotyping cytochrome P450 enzymes in the treatment of depression , 2015, Expert opinion on drug metabolism & toxicology.

[6]  Oliver Burk,et al.  Direct Transcriptional Regulation of Human Hepatic Cytochrome P450 3A4 (CYP3A4) by Peroxisome Proliferator–Activated Receptor Alpha (PPARα) , 2013, Molecular Pharmacology.

[7]  U. Zanger,et al.  Genetics, Epigenetics, and Regulation of Drug‐Metabolizing Cytochrome P450 Enzymes , 2014, Clinical pharmacology and therapeutics.

[8]  Teri E. Klein,et al.  Incorporation of Pharmacogenomics into Routine Clinical Practice: the Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline Development Process , 2014, Current drug metabolism.

[9]  K. Hillgren,et al.  PhRMA White Paper on ADME Pharmacogenomics , 2008, Journal of clinical pharmacology.

[10]  I. Zineh,et al.  Generating and weighing evidence in drug development and regulatory decision making: 5th US FDA-DIA workshop on pharmacogenomics. , 2010, Pharmacogenomics.

[11]  I. Zineh,et al.  Consistency of drug-drug and gene-drug interaction information in US FDA-approved drug labels. , 2013, Pharmacogenomics.

[12]  C. Dietrich,et al.  Effect of drug transporter pharmacogenetics on cholestasis , 2014, Expert opinion on drug metabolism & toxicology.

[13]  Y. Daali,et al.  Prediction by pharmacogenetics of safety and efficacy of non-steroidal anti- inflammatory drugs: a review. , 2014, Current drug metabolism.

[14]  W. Sadee,et al.  Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs , 2011, The Pharmacogenomics Journal.

[15]  H. Yamazaki,et al.  Comparison of kinetic parameters for drug oxidation rates and substrate inhibition potential mediated by cytochrome P450 3A4 and 3A5. , 2008, Current drug metabolism.

[16]  Yoshiaki Uyama,et al.  Pharmacogenetics in the evaluation of new drugs: a multiregional regulatory perspective , 2013, Nature Reviews Drug Discovery.

[17]  K. Papadakis,et al.  Pharmacogenetics of inflammatory bowel disease. , 2014, Pharmacogenomics.

[18]  Issam Zineh,et al.  DNA, drugs and chariots: on a decade of pharmacogenomics at the US FDA. , 2010, Pharmacogenomics.

[19]  I. Cascorbi,et al.  Polymorphisms of the drug transporters ABCB1, ABCG2, ABCC2 and ABCC3 and their impact on drug bioavailability and clinical relevance , 2014, Expert opinion on drug metabolism & toxicology.

[20]  S. Winter,et al.  Expression Variability of Absorption, Distribution, Metabolism, Excretion–Related MicroRNAs in Human Liver: Influence of Nongenetic Factors and Association with Gene Expression , 2013, Drug Metabolism and Disposition.

[21]  S‐M Huang,et al.  Is This the Drug or Dose for You?: Impact and Consideration of Ethnic Factors in Global Drug Development, Regulatory Review, and Clinical Practice , 2008, Clinical pharmacology and therapeutics.

[22]  B. Ploeger,et al.  Mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modeling in translational drug research. , 2008, Trends in pharmacological sciences.

[23]  J. Kitzmiller,et al.  Pharmacogenetics of Statin-Induced Myopathy: A Focused Review of the Clinical Translation of Pharmacokinetic Genetic Variants , 2014, Journal of pharmacogenomics & pharmacoproteomics.

[24]  Gavin R. Oliver,et al.  Bioinformatics for clinical next generation sequencing. , 2015, Clinical chemistry.

[25]  H. Guchelaar,et al.  Pharmacogenetics: From Bench to Byte— An Update of Guidelines , 2011, Clinical pharmacology and therapeutics.